Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
Rhea-AI Summary
Silo Pharma (NASDAQ: SILO) has filed a new provisional patent application with the USPTO for its lead asset SPC-15, expanding its intellectual property portfolio. The patent covers a dual-action method and composition for treating stress-induced psychiatric disorders.
A preclinical study demonstrated that the combination of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, with an N-methyl-D-aspartate receptor (NMDAR) antagonist showed significant improvements in behavioral outcomes and reduced severe stress-induced conditions. This technology was originally licensed through a collaboration with Columbia University.
The company has also recently filed a separate expanded provisional patent application focusing on chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
Positive
- Filing of new provisional patent application strengthening IP protection for lead asset SPC-15
- Preclinical study showed significant improvement in behavioral outcomes
- Multiple patent applications pending to expand protection of core technology
Negative
- Product still in early development stage (preclinical)
- No guarantee of patent approval or commercial success
Insights
This patent filing represents a significant strategic development for Silo Pharma's intellectual property portfolio, particularly in the rapidly evolving field of psychiatric pharmaceuticals. The dual-mechanism approach combining a 5-HT4R agonist with an NMDAR antagonist is particularly noteworthy, as it addresses multiple neural pathways involved in stress-induced disorders. This approach could potentially offer superior efficacy compared to single-target treatments.
The provisional patent strategy deserves careful attention. While it provides immediate protection and establishes a priority date, Silo will have 12 months to file a complete patent application. This timing suggests a well-planned IP strategy, building upon their existing patents from the Columbia University collaboration. The expanded patent coverage for chronic, combinatorial targeting indicates a comprehensive approach to protect various aspects of the technology.
From a market perspective, the preclinical success in reducing stress-induced conditions positions Silo in the growing mental health therapeutics sector, valued at over
The strategic value extends beyond the immediate patent filing. This IP expansion strengthens Silo's negotiating position for potential partnerships or licensing agreements, while also creating barriers to entry for competitors. The combination treatment's demonstrated efficacy in preclinical studies suggests potential applications across multiple stress-related conditions, possibly expanding the addressable market.
SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders
SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15.
Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University.
The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A preclinical study of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, combined with an N-methyl-D-aspartate receptor (NMDAR) antagonist demonstrated significant improvement in behavioral outcomes and a marked reduction in severe stress-induced conditions.
“We believe that the SPC-15 combination treatment is showing promise in multiple stress-induced behaviors and disorders. This provisional patent application, if approved and the patent issued, will augment and expand the existing patents on this technology which we originally acquired through our global license agreement,” said Eric Weisblum, CEO of Silo.
Silo recently filed a separate expanded provisional patent application covering the chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the new patent application filed by Silo Pharma (SILO) for SPC-15 in February 2025?
What were the results of SILO's preclinical study for SPC-15 combination treatment?
How many patent applications does Silo Pharma (SILO) currently have for SPC-15?
Where did Silo Pharma originally obtain the SPC-15 technology?
